Please login to the form below

Not currently logged in
Email:
Password:

Sangamo

This page shows the latest Sangamo news and features for those working in and with pharma, biotech and healthcare.

Roche's O’Day swaps big pharma for big biotech

Roche's O’Day swaps big pharma for big biotech

with Sangamo to use its zinc finger gene-editing platform for drug discovery, and a $1.2bn deal to acquire Nimbus Therapeutics and its non-alcoholic steatohepatitis (NASH) candidate selonsertib.

Latest news

More from news
Approximately 6 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics